Drug Repurposing for Reducing the Size of Benign Thyroid Nodules: A Systematic Review
Metformin shows the most consistent potential for noninvasive reduction of BTN size, particularly in patients with metabolic comorbidities. However, current evidence is limited and heterogeneous. Further large-scale studies are needed to confirm efficacy and guide clinical use.
Authors
- David Toro-Tobón (ORCID: https://orcid.org/0000-0003-1910-4144)
- Naykky Singh Ospina (ORCID: https://orcid.org/0000-0001-7229-5061)
- Fernando Rivadeneira (ORCID: https://orcid.org/0000-0001-9435-9441)
- Misk Al Zahidy (ORCID: https://orcid.org/0009-0007-1999-9351)
- Juan Pablo Brito (ORCID: https://orcid.org/0000-0003-1840-1745)
- Oscar J. Ponce (ORCID: https://orcid.org/0000-0001-5729-8408)
- Michèle Montero
- Cristian Soto Jacome (ORCID: https://orcid.org/0000-0002-6186-748X)
- Andrea Arce-Camposano
- Francisco E Fierro
Institutions
- Norwalk Hospital (US)
- Mayo Clinic (US)
- Central University of Ecuador (EC)
- University of Guayaquil (EC)
- University of Florida Health (US)
- Derriford Hospital (GB)
- University of Florida (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
- University Hospitals Plymouth NHS Trust (GB)
- Universidad San Francisco de Quito (EC)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2025-11-11
- DOI
- https://doi.org/10.1210/clinem/dgaf616
- Citations
- 1
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.81